{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:37:12Z","timestamp":1774424232618,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"13-14","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Due to the overuse of antibiotics, infections, in particular those caused by multidrug-resistant bacteria, are becoming more and more frequent. Despite the worldwide introduction of antibiotic therapy, vaccines and constant improvements in hygiene, the burden of multidrug-resistant bacterial infections is increasing and is expected to rise in the future. The development of monoclonal therapeutic antibodies and specific immunomodulatory drugs represent new treatment options in the fight against infectious diseases. This article provides a\u00a0brief overview of recent advances in immunomodulatory therapy and other strategies in the treatment of infectious disease.<\/jats:p>","DOI":"10.1007\/s00508-020-01746-2","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T09:03:27Z","timestamp":1608109407000},"page":"714-720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunotherapy and vaccination against infectious diseases"],"prefix":"10.1007","volume":"133","author":[{"given":"Meinolf","family":"Ebbers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph J.","family":"Hemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"M\u00fcller-Hilke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil C.","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"1746_CR1","volume-title":"Plotkin\u2019s vaccines","author":"SA Plotkin","year":"2018","unstructured":"Plotkin\u00a0SA, Orenstein\u00a0W, Offit\u00a0P, Edwards KM.\u00a0Plotkin\u2019s vaccines. 7th\u00a0ed. Amsterdam: Elsevier; 2018.","edition":"7"},{"key":"1746_CR2","unstructured":"U.S. National Library of Medicine. History of medicine. 2019. https:\/\/www.nlm.nih.gov\/exhibition\/smallpox\/sp_variolation.html. Accessed 27 Aug 2019."},{"key":"1746_CR3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/fmb.09.17","volume":"4","author":"DT Nardelli","year":"2009","unstructured":"Nardelli\u00a0DT, Munson\u00a0EL, Callister\u00a0SM, Schell\u00a0RF. Human Lyme disease vaccines: past and future concerns. Future Microbiol. 2009;4:457\u201369.","journal-title":"Future Microbiol"},{"key":"1746_CR4","doi-asserted-by":"crossref","unstructured":"Feldman MF, Mayer Bridwell AE, Scott NE, Vinogradov E, McKee SR, Chavez SM, et\u00a0al. A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae. Proc Natl Acad Sci. 2019;116(37):18655\u201363.","DOI":"10.1073\/pnas.1907833116"},{"key":"1746_CR5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"AE Gorbalenya","year":"2020","unstructured":"Gorbalenya\u00a0AE, Baker\u00a0SC, Baric\u00a0RS. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV\u20112. Nat Microbiol. 2020;5:536\u201344.","journal-title":"Nat Microbiol"},{"key":"1746_CR6","unstructured":"Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.. https:\/\/gisanddata.maps.arcgis.com\/apps\/opsdashboard\/index.html#\/bda7594740fd40299423467b48e9ecf6. Accessed 12 May 2020."},{"key":"1746_CR7","unstructured":"The World Health Organization (WHO). Draft landscape of COVID-19 candidate vaccines.. https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines. Accessed 11 May 2020."},{"issue":"6","key":"1746_CR8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJMc2013400","volume":"383","author":"PJ Halfmann","year":"2020","unstructured":"Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, et al. Transmission of SARS-CoV\u20112 in Domestic Cats. N\u00a0Engl J Med. 2020;383(6):592\u20134.","journal-title":"Cats. N\u00a0Engl J Med."},{"key":"1746_CR9","unstructured":"United States National Library of Medicine at the National Institutes of Health; 2019. https:\/\/clinicaltrials.gov."},{"key":"1746_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","volume":"24","author":"SJ Draper","year":"2018","unstructured":"Draper\u00a0SJ, Sack\u00a0BK, King\u00a0CR, Nielsen\u00a0CM, Rayner\u00a0JC, Higgins\u00a0MK, et\u00a0al. Malaria vaccines: recent advances and new horizons. Cell Host Microbe. 2018;24:43\u201356.","journal-title":"Cell Host Microbe"},{"key":"1746_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS SCTP","year":"2015","unstructured":"RTS SCTP. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a\u00a0booster dose in infants and children in Africa: final results of a\u00a0phase 3, individually randomised, controlled trial. Lancet. 2015;386:31\u201345.","journal-title":"Lancet"},{"key":"1746_CR12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(19)31567-3","volume":"394","author":"L Schuerman","year":"2019","unstructured":"Schuerman\u00a0L. RTS,S malaria vaccine could provide major public health benefits. Lancet. 2019;394:735\u20136.","journal-title":"Lancet"},{"key":"1746_CR13","volume-title":"World Malaria Report 2018","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. World Malaria Report 2018. 2010."},{"key":"1746_CR14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s40471-015-0041-9","volume":"2","author":"JD Cherry","year":"2015","unstructured":"Cherry\u00a0JD. The history of pertussis (whooping cough); 1906\u20132015: facts, myths, and misconceptions. Curr Epidemiol Rep. 2015;2:120\u201330.","journal-title":"Curr Epidemiol Rep"},{"key":"1746_CR15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cmdc.201200487","volume":"8","author":"PM Moyle","year":"2013","unstructured":"Moyle\u00a0PM, Toth\u00a0I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem. 2013;8:360\u201376.","journal-title":"ChemMedChem"},{"key":"1746_CR16","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","volume":"2","author":"T Ura","year":"2014","unstructured":"Ura\u00a0T, Okuda\u00a0K, Shimada\u00a0M. Developments in viral vector-based vaccines. Vaccines. 2014;2:624\u201341.","journal-title":"Vaccines"},{"key":"1746_CR17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7774\/cevr.2013.2.2.97","volume":"2","author":"Y Choi","year":"2013","unstructured":"Choi\u00a0Y, Chang\u00a0J. Viral vectors for vaccine applications. Clin Exp Vaccine Res. 2013;2:97.","journal-title":"Clin Exp Vaccine Res"},{"key":"1746_CR18","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3390\/v5102384","volume":"5","author":"S Brandler","year":"2013","unstructured":"Brandler\u00a0S, Tangy\u00a0F. Vaccines in development against West Nile virus. Viruses. 2013;5:2384\u2013409.","journal-title":"Viruses"},{"key":"1746_CR19","first-page":"1","volume":"6736","author":"EC Reisinger","year":"2018","unstructured":"Reisinger\u00a0EC, Tschismarov\u00a0R, Beubler\u00a0E, Wiedermann\u00a0U, Firbas\u00a0C, Loebermann\u00a0M, et al. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a\u00a0double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet. 2018;6736:1\u201310.","journal-title":"Lancet"},{"key":"1746_CR20","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrmicro2668","volume":"9","author":"SA Plotkin","year":"2011","unstructured":"Plotkin\u00a0SA, Plotkin\u00a0SL. The development of vaccines: how the past led to the future. Nat Rev Microbiol. 2011;9:889\u201393.","journal-title":"Nat Rev Microbiol"},{"key":"1746_CR21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0140-6736(90)90802-C","volume":"335","author":"EC Reisinger","year":"1990","unstructured":"Reisinger EC, Kern P, Dietrich M, Ernst M, Flad HD, et al. Inhibition of HIV progression by dithiocarb. Zeitschrift f\u00fcr Chemotherapie 1\/2005. ZFC. Lancet 1990;335:679\u201382.","journal-title":"Lancet"},{"key":"1746_CR22","doi-asserted-by":"crossref","first-page":"e2371","DOI":"10.1371\/journal.pone.0002371","volume":"3","author":"L Polonelli","year":"2008","unstructured":"Polonelli\u00a0L, Pont\u00f3n\u00a0J, Elguezabal\u00a0N, Moragues\u00a0MD, Casoli\u00a0C, Pilotti\u00a0E, et al. Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. Plos One. 2008;3:e2371.","journal-title":"Plos One"},{"key":"1746_CR23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tim.2018.12.009","volume":"27","author":"D Raafat","year":"2019","unstructured":"Raafat\u00a0D, Otto\u00a0M, Reppschl\u00e4ger\u00a0K, Iqbal\u00a0J, Holtfreter\u00a0S. Fighting staphylococcus aureus biofilms with monoclonal antibodies. Trends Microbiol. 2019;27:303\u201322.","journal-title":"Trends Microbiol"},{"key":"1746_CR24","doi-asserted-by":"crossref","first-page":"e0190537","DOI":"10.1371\/journal.pone.0190537","volume":"13","author":"AK Varshney","year":"2018","unstructured":"Varshney\u00a0AK, Kuzmicheva\u00a0GA, Lin\u00a0J, Sunley\u00a0KM, Bowling\u00a0RA, Kwan\u00a0T\u2011Y, et al. A natural human monoclonal antibody targeting staphylococcus protein A protects against Staphylococcus aureus bacteremia. PLoS ONE. 2018;13:e190537.","journal-title":"PLoS ONE"},{"key":"1746_CR25","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/infdis\/jiy597","volume":"219","author":"X Chen","year":"2019","unstructured":"Chen\u00a0X, Sun\u00a0Y, Missiakas\u00a0D, Schneewind\u00a0O. Staphylococcus aureus decolonization of mice with monoclonal antibody neutralizing protein A. J\u00a0Infect Dis. 2019;219:884\u20138.","journal-title":"J Infect Dis"},{"key":"1746_CR26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1080\/00365540801964960","volume":"40","author":"E Mattila","year":"2008","unstructured":"Mattila\u00a0E, Anttila\u00a0V\u2011J, Broas\u00a0M, Marttila\u00a0H, Poukka\u00a0P, Kuusisto\u00a0K, et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: Efficacy and safety data of a\u00a0prematurely interrupted trial. Scand J Infect Dis. 2008;40:702\u20138.","journal-title":"Scand J Infect Dis"},{"key":"1746_CR27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","volume":"376","author":"MH Wilcox","year":"2017","unstructured":"Wilcox\u00a0MH, Gerding\u00a0DN, Poxton\u00a0IR, Kelly\u00a0C, Nathan\u00a0R, Birch\u00a0T, et\u00a0al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N\u00a0Engl J Med. 2017;376:305\u201317.","journal-title":"N Engl J Med"},{"key":"1746_CR28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/21645515.2017.1395538","volume":"14","author":"O Matsuoka","year":"2018","unstructured":"Matsuoka\u00a0O, Patel\u00a0DM, Sasaki\u00a0S, Oka\u00a0H, Sasaki\u00a0T, Pietrobon\u00a0PJ, et\u00a0al. Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults. Hum Vaccin Immunother. 2018;14:322\u20138.","journal-title":"Hum Vaccin Immunother"},{"key":"1746_CR29","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/a-0882-7530","volume":"144","author":"EC Reisinger","year":"2019","unstructured":"Reisinger\u00a0EC, Ebbers\u00a0M, L\u00f6bermann\u00a0M. Clostridium difficile: Antik\u00f6rpertherapie und Impfungen. Dtsch Med Wochenschr. 2019;144:842\u20139.","journal-title":"Dtsch Med Wochenschr"},{"key":"1746_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcimb.2019.00002","volume":"9","author":"BC Wilson","year":"2019","unstructured":"Wilson\u00a0BC, Vatanen\u00a0T, Cutfield\u00a0WS, O\u2019Sullivan\u00a0JM. The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol. 2019;9:1\u201311.","journal-title":"Front Cell Infect Microbiol"},{"key":"1746_CR31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhin.2019.03.010","volume":"102","author":"V Tavoukjian","year":"2019","unstructured":"Tavoukjian\u00a0V. Faecal microbiota transplantation for the decolonization of antibiotic-resistant bacteria in the gut: a\u00a0systematic review and meta-analysis. J\u00a0Hosp Infect. 2019;102:174\u201388.","journal-title":"J Hosp Infect"},{"key":"1746_CR32","unstructured":"U.S. Food & Drug Administration. 2019. https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-warns-about-potential-risk-serious-infections-caused-multi-drug-resistant-organisms. Accessed 28 Aug 2019."},{"key":"1746_CR33","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","volume":"94","author":"L Pape","year":"2015","unstructured":"Pape\u00a0L, Hartmann\u00a0H, Bange\u00a0FC, Suerbaum\u00a0S, Bueltmann\u00a0E, Ahlenstiel-Grunow\u00a0T. Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine. 2015;94:e1000.","journal-title":"Medicine"},{"key":"1746_CR34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara\u00a0LA, Topaz\u00a0N, Wang\u00a0X, Hariri\u00a0S, Fox\u00a0L, MacNeil\u00a0JR. High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine. Mmwr Morb Mortal Wkly Rep. 2017;66:734\u20137.","journal-title":"Mmwr Morb Mortal Wkly Rep"},{"key":"1746_CR35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.spid.2004.02.001","volume":"15","author":"BL Ligon","year":"2004","unstructured":"Ligon\u00a0BL. Penicillin: its discovery and early development. Semin Pediatr Infect Dis. 2004;15:52\u20137.","journal-title":"Semin Pediatr Infect Dis"},{"key":"1746_CR36","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10295-009-0553-8","volume":"36","author":"R Bentley","year":"2009","unstructured":"Bentley\u00a0R. Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence \u03b2\u2011lactams). J\u00a0Ind Microbiol Biotechnol. 2009;36:775\u201386.","journal-title":"J Ind Microbiol Biotechnol"},{"key":"1746_CR37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(17)30235-9","volume":"17","author":"RJ Vickers","year":"2017","unstructured":"Vickers\u00a0RJ, Tillotson\u00a0GS, Nathan\u00a0R, Hazan\u00a0S, Pullman\u00a0J, Lucasti\u00a0C, et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a\u00a0phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis. 2017;17:735\u201344.","journal-title":"Lancet Infect Dis"},{"key":"1746_CR38","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/jac\/dkv498","volume":"71","author":"E Bass\u00e8res","year":"2016","unstructured":"Bass\u00e8res\u00a0E, Endres\u00a0BT, Khaleduzzaman\u00a0M, Miraftabi\u00a0F, Alam\u00a0MJ, Vickers\u00a0RJ, et\u00a0al. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a\u00a0novel treatment for C. difficile infection. J\u00a0Antimicrob Chemother. 2016;71:1245\u201351.","journal-title":"J Antimicrob Chemother"},{"key":"1746_CR39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nbt.3037","volume":"33","author":"BD Henry","year":"2015","unstructured":"Henry\u00a0BD, Neill\u00a0DR, Becker\u00a0KA, Gore\u00a0S, Bricio-Moreno\u00a0L, Ziobro\u00a0R, et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol. 2015;33:81\u20138.","journal-title":"Nat Biotechnol"},{"key":"1746_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.00491-18","volume":"92","author":"J Brozy","year":"2018","unstructured":"Brozy\u00a0J, Schlaepfer\u00a0E, Mueller\u00a0CKS, Rochat\u00a0M\u2011A, Rampini\u00a0SK, Myburgh\u00a0R, et al. Antiviral activity of HIV gp120-targeting bispecific T cell engager antibody constructs. J\u00a0Virol. 2018;92:1\u201313.","journal-title":"J Virol"},{"key":"1746_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-26190-1","volume":"8","author":"Y Ophinni","year":"2018","unstructured":"Ophinni\u00a0Y, Inoue\u00a0M, Kotaki\u00a0T, Kameoka\u00a0M. CRISPR\/Cas9 system targeting regulatory genes of HIV\u20111 inhibits viral replication in infected T\u2011cell cultures. Sci Rep. 2018;8:1\u201312.","journal-title":"Sci Rep"},{"key":"1746_CR42","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41467-019-10366-y","volume":"10","author":"PK Dash","year":"2019","unstructured":"Dash\u00a0PK, Kaminski\u00a0R, Bella\u00a0R, Su\u00a0H, Mathews\u00a0S, Ahooyi\u00a0TM, et al. Sequential LASER ART and CRISPR treatments eliminate HIV\u20111 in a\u00a0subset of infected humanized mice. Nat Commun. 2019;10:2753.","journal-title":"Nat Commun"},{"key":"1746_CR43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/d41586-018-07545-0","volume":"563","author":"D Cyranoski","year":"2018","unstructured":"Cyranoski D. Genome-edited baby claim provokes international outcry. Nature. 2018;563:607\u20138","journal-title":"Nature"},{"key":"1746_CR44","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s13059-014-0516-x","volume":"15","author":"CL Beisel","year":"2014","unstructured":"Beisel\u00a0CL, Gomaa\u00a0AA, Barrangou\u00a0R. A CRISPR design for next-generation antimicrobials. Genome Biol. 2014;15:516.","journal-title":"Genome Biol"},{"key":"1746_CR45","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick\u00a0RM, Guerrero-Bustamante\u00a0CA, Garlena\u00a0RA, Russell\u00a0DA, Ford\u00a0K, Harris\u00a0K, et al. Engineered bacteriophages for treatment of a\u00a0patient with a\u00a0disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25:730\u20133.","journal-title":"Nat Med"},{"key":"1746_CR46","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain\u00a0M, Rivi\u00e8re\u00a0I, Riddell\u00a0S. Therapeutic T cell engineering. Nature. 2017;545:423\u201331.","journal-title":"Nature"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-020-01746-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T10:40:30Z","timestamp":1626777630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-020-01746-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":46,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1746"],"URL":"https:\/\/doi.org\/10.1007\/s00508-020-01746-2","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]},"assertion":[{"value":"27 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Ebbers, C.J.\u00a0Hemmer, B.\u00a0M\u00fcller-Hilke and E.C.\u00a0Reisinger declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}